Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Gross Profit (2022 - 2025)

Historic Gross Profit for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $87000.0.

  • BioXcel Therapeutics' Gross Profit rose 10910.04% to $87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$212000.0, marking a year-over-year decrease of 18480.0%. This contributed to the annual value of $123000.0 for FY2024, which is 250.0% up from last year.
  • BioXcel Therapeutics' Gross Profit amounted to $87000.0 in Q3 2025, which was up 10910.04% from $13000.0 recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Gross Profit high stood at $1.0 million for Q2 2024, and its period low was -$956000.0 during Q3 2024.
  • Moreover, its 4-year median value for Gross Profit was $126000.0 (2022), whereas its average is $65384.6.
  • Data for BioXcel Therapeutics' Gross Profit shows a peak YoY increase of 15482.23% (in 2024) and a maximum YoY decrease of 45906.43% (in 2024) over the last 5 years.
  • BioXcel Therapeutics' Gross Profit (Quarter) stood at $229000.0 in 2022, then plummeted by 247.6% to -$338000.0 in 2023, then plummeted by 37.87% to -$466000.0 in 2024, then surged by 118.67% to $87000.0 in 2025.
  • Its Gross Profit was $87000.0 in Q3 2025, compared to $13000.0 in Q2 2025 and $154000.0 in Q1 2025.